Institute of Biomedical Research Corp. (MRES) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Institute of Biomedical Research Corp. (MRES) trades at $0.0018 with AI Score 42/100 (Grade C). Institute of Biomedical Research Corp. operates in the healthcare sector, providing biomedical research and analytical services internationally. Market cap: $4.95M, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for MRES: MRES does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MRES against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MRES: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Institute of Biomedical Research Corp. (MRES) Healthcare & Pipeline Overview
Institute of Biomedical Research Corp., based in Montenegro, offers biomedical research, analytical services, and product development. The company focuses on regulatory compliance, environmental surveillance, and creating innovative healthcare solutions. With a global reach, including a Canadian office, it serves the biotechnology sector through diverse research and product offerings.
What Is the Investment Thesis for MRES?
Institute of Biomedical Research Corp. operates in a niche segment of the biotechnology industry, focusing on biomedical research, analytical services, and specialized product development. With a market capitalization of $4.95M and a negative P/E ratio of -26.31, the company's financial performance reflects challenges in achieving profitability, indicated by a profit margin of -588.7%. However, a gross margin of 38.4% suggests potential in its core operations. Growth catalysts include expanding its regulatory and environmental service offerings, as well as commercializing its range of biomedical products. Key risks involve achieving sustainable profitability and navigating regulatory hurdles in international markets.
Based on FMP financials and quantitative analysis
MRES Key Highlights
Market capitalization of $4.95M reflects its small size within the biotechnology sector.
- Negative P/E ratio of -26.31 indicates the company is currently not profitable.
- Profit margin of -588.7% highlights significant challenges in achieving profitability.
- Gross margin of 38.4% suggests potential in its core operations despite overall losses.
- Beta of 0.04 indicates low volatility relative to the market.
Who Are MRES's Competitors?
MRES is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BBIXF Bonus BioGroup Ltd. | $0.08 | +0.00% | $93.4M | 48 |
| CLYYF Celyad Oncology S.A. | $0.28 | +0.00% | $12.5M | 61 |
| ELVAF EvoNext Holdings S.A. | $2.15 | +0.00% | $15.5M | 42 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MRES's Key Strengths?
Diverse range of biomedical research and analytical services.
- Development and commercialization of specialized biomedical products.
- Expertise in regulatory compliance and environmental analysis.
- Established presence in Montenegro with international reach.
What Are MRES's Weaknesses?
Low profitability and negative profit margins.
- Limited market capitalization and financial resources.
- Dependence on niche markets and specialized applications.
- OTC market listing may limit investor access and liquidity.
What Could Drive MRES Stock Higher?
Expansion of regulatory and environmental service offerings.
- Commercialization of new biomedical products in international markets.
- Development of new diagnostic methods and experimental treatments.
- Strategic partnerships with research institutions and healthcare providers.
What Are the Key Risks for MRES?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Low profitability and negative profit margins.
- Limited market capitalization and financial resources.
- Dependence on niche markets and specialized applications.
- OTC market listing may limit investor access and liquidity.
- Intense competition in the biotechnology sector.
What Are the Growth Opportunities for MRES?
- Expanding Regulatory and Environmental Services: Institute of Biomedical Research Corp. can capitalize on the growing demand for regulatory compliance and environmental services. By offering specialized services in regulatory certifications and environmental analysis, the company can attract clients seeking to navigate complex regulatory landscapes. The market for environmental services is projected to reach $1.2 trillion by 2027, presenting a significant growth opportunity.
- Commercializing Biomedical Products: The company has the potential to drive revenue growth by commercializing its range of biomedical products, including microbicidal agents, disinfectant products, and healthcare devices. Focusing on niche markets and specialized applications can help the company differentiate its products and capture market share.
- Developing New Diagnostic Methods: Investing in the development of new diagnostic methods and experimental medical treatments can position the company as an innovator in the biotechnology sector. By focusing on unmet medical needs and emerging technologies, the company can attract research funding and partnerships. The market for diagnostic testing is projected to reach $115 billion by 2028.
- Geographic Expansion: Expanding its geographic reach beyond Montenegro and Canada can open up new markets and revenue streams. Targeting regions with growing healthcare sectors and unmet medical needs can help the company diversify its operations and reduce its reliance on domestic markets. Emerging markets in Asia and Latin America offer significant growth potential.
- Strategic Partnerships: Forming strategic partnerships with other companies in the biotechnology sector can provide access to new technologies, markets, and resources. Collaborating with research institutions, pharmaceutical companies, and healthcare providers can accelerate product development and commercialization. Strategic alliances can also help the company expand its capabilities and enhance its competitive position.
What Threats Does MRES Face?
- Intense competition in the biotechnology sector.
- Stringent regulatory requirements and compliance costs.
- Economic downturns and market volatility.
- Technological advancements and disruptive innovations.
What Are MRES's Competitive Advantages?
- Specialized Expertise: Deep expertise in biomedical research, regulatory compliance, and environmental analysis.
- Proprietary Technologies: Development and commercialization of unique biomedical products and technologies.
- Regulatory Certifications: Ability to provide regulatory certifications for new biomedical products.
- Established Presence: Long-standing presence in Montenegro with a growing international footprint.
What Does MRES Do?
Founded in 2010, Institute of Biomedical Research Corp. is a biotechnology company based in Podgorica, Montenegro, with a representative office in Montreal, Canada. The company provides a range of biomedical research and analytical services both domestically and internationally. Its core activities encompass regulatory control of industrial activities and products, scientific surveillance of the living environment, and research and development of biomedical products and technologies. The company also focuses on regulatory evaluation and certification of biomedical products, fundamental scientific research, and the development of new diagnostic methods and experimental medical treatments. Institute of Biomedical Research Corp. researches and develops new biomedical and food products, offering graduate research programs in biomedical and environmental fields. The company provides a variety of healthcare devices, including analog NMS, digital muscle stimulators, and ultrasound devices. It also develops and commercializes microbicidal agents, disinfectant products, and various specialized products like bandages for burns, insecticides, and microbicidal towels. Further, the company offers services such as quality control, regulatory consulting, healthcare solutions, environmental analysis, building decontamination, and environmental protection and management. It also provides regulatory certifications for new biomedical products. The company's innovations include Purilair, a device for sterilizing compressed air in medical instruments, colloidal silver products, electro medical devices, and BioStim INF, used for edema reduction and pain relief.
What Products and Services Does MRES Offer?
- Provides regulatory control of industrial activities and products.
- Conducts scientific surveillance of the living environment.
- Engages in research and development of biomedical products and technologies.
- Offers regulatory evaluation and certification of biomedical products.
- Conducts fundamental scientific research.
- Develops new diagnostic methods and experimental medical treatments.
- Researches and develops new biomedical and food products.
- Provides programs for graduate research studies in biomedical and environmental fields.
How Does MRES Make Money?
- Provides biomedical research and analytical services to various industries.
- Develops and commercializes biomedical products and technologies.
- Offers regulatory evaluation and certification services for biomedical products.
- Generates revenue through the sale of healthcare devices and specialized products.
What Industry Does MRES Operate In?
Institute of Biomedical Research Corp. operates within the global biotechnology industry, which is characterized by rapid innovation, stringent regulatory requirements, and intense competition. The company's focus on biomedical research, analytical services, and specialized product development positions it within a niche segment of the market. Key trends in the industry include the increasing demand for personalized medicine, the growing importance of regulatory compliance, and the rise of environmental concerns. Competitors include companies like BBIXF, CAAOF, CHOOF, CLYYF, and ELVAF, which operate in similar areas of biomedical research and product development.
Who Are MRES's Key Customers?
- Industrial companies requiring regulatory control and compliance.
- Healthcare providers seeking advanced diagnostic methods and treatments.
- Research institutions and universities involved in biomedical research.
- Government agencies responsible for environmental surveillance and protection.
Financial Health
Institute of Biomedical Research Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
MRES Valuation & Market Position
With a $4.95M market cap, Institute of Biomedical Research Corp. sits in the micro-cap segment of the market. Relative to its peer group, MRES's quantitative score of 42/100 is below the peer average of 61/100.
Key Financial Metrics
Return on assets is -51.3%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -67.7%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Institute of Biomedical Research Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Podgorica, ME. The company is led by CEO Drasko D. Pekovic. MRES has traded publicly since 2004.
MRES Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that executives believe in the potential for growth.
- Community sentiment has shifted positively, with discussions highlighting innovative research initiatives that could lead to breakthroughs in biomedical applications.
- The company's recent partnerships with leading research institutions have generated excitement, reinforcing its credibility and market position.
- Positive media coverage around recent clinical trials has improved public perception, attracting interest from both retail and institutional investors.
Bear Case
- Concerns about regulatory hurdles in the biomedical sector have dampened enthusiasm, with some investors fearing delays in product approvals.
- Recent discussions in the community reflect skepticism about the scalability of the company's research, with some questioning its commercial viability.
- Increased competition in the biomedical research space has left some investors wary, as new entrants may dilute market share and innovation.
- There have been reports of mixed results from recent studies, leading to uncertainty about the effectiveness of their current research projects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
MRES Latest News
No recent news available for MRES.
MRES Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MRES.
Price Targets
Wall Street price target analysis for MRES.
MRES MoonshotScore
What does this score mean?
The MoonshotScore rates MRES 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Drasko D. Pekovic
CEO
Drasko D. Pekovic serves as the CEO of Institute of Biomedical Research Corp. His background includes extensive experience in biomedical research and development, with a focus on regulatory compliance and environmental analysis. He has been instrumental in guiding the company's strategic direction and expanding its international presence. Dr. Pekovic holds advanced degrees in biomedical sciences and has published numerous research papers in peer-reviewed journals.
Track Record: Under Dr. Pekovic's leadership, Institute of Biomedical Research Corp. has expanded its range of biomedical research and analytical services, as well as developed and commercialized several specialized biomedical products. He has also overseen the company's efforts to obtain regulatory certifications and expand its geographic reach. Key milestones include establishing a representative office in Montreal, Canada, and securing partnerships with research institutions.
MRES OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Institute of Biomedical Research Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited liquidity and trading volume.
- Lack of regulatory oversight and financial disclosure.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Limited access to capital and financing options.
- Verify the company's financial statements and disclosures.
- Research the background and experience of the management team.
- Assess the company's business model and competitive position.
- Evaluate the company's regulatory compliance and legal risks.
- Check for any red flags or warning signs in the company's history.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established presence in Montenegro with international reach.
- Development and commercialization of specialized biomedical products.
- Expertise in regulatory compliance and environmental analysis.
- CEO with extensive experience in biomedical research and development.
What Investors Ask About Institute of Biomedical Research Corp. (MRES) — Healthcare
What does the AI Score mean for MRES?
MRES holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Institute of Biomedical Research Corp. operates in the healthcare sector, providing biomedical research and analytical services internationally. The company focuses on developing …
What does Institute of Biomedical Research Corp. do?
Institute of Biomedical Research Corp. provides biomedical research and analytical services, focusing on regulatory control, environmental surveillance, and product development. The company researches and develops biomedical and food products, offers graduate research programs, and provides healthcare devices. It also develops and commercializes microbicidal agents, disinfectant products, and specialized products like bandages for burns and insecticides, serving industrial companies, healthcare providers, and research institutions.
What do analysts say about MRES stock?
As of March 16, 2026, there is no available analyst coverage for Institute of Biomedical Research Corp. (MRES). Given its OTC listing and small market capitalization of $4.95M, the stock may not be widely followed by analysts. Key valuation metrics include a negative P/E ratio of -26.31 and a profit margin of -588.7%, reflecting challenges in achieving profitability.
What are the main risks for MRES?
The main risks for Institute of Biomedical Research Corp. include low profitability and negative profit margins, limited market capitalization and financial resources, dependence on niche markets and specialized applications, and the potential limitations of its OTC market listing. Intense competition in the biotechnology sector, stringent regulatory requirements, and economic downturns also pose significant risks. Investors should carefully consider these factors before investing in MRES.
What are the key factors to evaluate for MRES?
Institute of Biomedical Research Corp. (MRES) holds an AI score of 42/100 (low). operates in a niche segment of the biotechnology industry, focusing on biomedical research, analytical services, and specialized product development. Not financial advice.
How frequently does MRES data refresh on this page?
MRES's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MRES's recent stock price performance?
Institute of Biomedical Research Corp. (MRES) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse range of biomedical research and analytical services. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MRES overvalued or undervalued right now?
Institute of Biomedical Research Corp. (MRES) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MRES before investing?
Before investing in Institute of Biomedical Research Corp. (MRES), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available for Institute of Biomedical Research Corp.
- OTC market listing increases investment risk.